A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women

New England Journal of Medicine

Volumn 372, Issue 8, 2014, Pages 711-723

  Joura, E A ^a   Giuliano, A R ^b   Iversen, O E ^c   Bouchard, C ^d   Mao, C ^f   Mehlsen, J ^g   Moreira, E D ⁱ   Ngan, Y ^j   Petersen, L K ^k   Lazcano Ponce, E ^l   Pitisuttithum, P ^m   Restrepo, J A ⁿ   Stuart, G ^e   Woelber, L ^o   Yang, Y C ^p   Cuzick, J ^q   Garland, S M ^r   Huh, W ^s   Kjaer, S K ^h   Bautista, O M ^t   Chan, I S F ^t   Chen, J ^t   Gesser, R ^t   Moeller, E ^t   Ritter, M ^t   Vuocolo, S ^t   Luxembourg, A ^t   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Rigshospitalet   (Denmark)

ⁱ INSTITUTO OSWALDO CRUZ   (Brazil)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^m MAHIDOL UNIVERSITY   (Thailand)

ⁿ Centro de Investigación Clínica Clinica Medellin Poblado   (Colombia)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p MACKAY MEMORIAL HOSPITAL   (Taiwan)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^r UNIVERSITY OF MELBOURNE   (Australia)

^s University of Alabama   (United States)

^t MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; INTRAEPITHELIAL NEOPLASIA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; VAGINA DISEASE; VIRUS IDENTIFICATION; VULVA CARCINOMA; ALPHAPAPILLOMAVIRUS; BLOOD; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; GENITAL DISEASES, FEMALE; IMMUNOLOGY; INCIDENCE; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND METHOD; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84923039975     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1405044     Document Type: Article

References (46)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
3. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and highrisk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30:1513-8.
4. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013;49:3450-61.
5. Hatch KD. A3. Vaginal intraepithelial neoplasia (VAIN). Int J Gynaecol Obstet 2006;94:Suppl 1:S40-S43.
6. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999;21:Suppl 1:S42-S48.
7. Picconi MA, Eiján AM, Distéfano AL, et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 2000;61:65-9.
8. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:Suppl:S20-S26.
9. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196:1447-54.
10. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-14.
11. Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2005;10:5-19.
12. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
13. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-85.
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
16. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
17. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
18. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
19. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012;31:109-13.
20. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106:djt460.
21. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
22. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645-51.
23. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012;130(2):e249-e256.
24. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93.
25. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87:544-7.
26. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012;102:833-5.
27. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012;206:860-6.
28. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013;40:130-5.
29. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013;20:17-20.
30. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906.
31. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010;29:95-101.
32. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
33. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011;29:8279-84.
34. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271:193-203.
35. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012;166:1140-8.
36. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014;275:398-408.
37. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf 2013;36:393-412.
38. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30:Suppl 5:F123-F138.
39. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014;23:1997-2008.
40. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7:38.
41. Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014;10:2174-103.
42. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Comm Stat Theory Methods 1998;27:1305-22.
43. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.don' Vaccine 2008;26:6844-51.
44. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
45. Wheeler C, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44.
46. Nygard M, Kjaer S, Dillner J, et al. Long-term effectiveness and immunogenicity of Gardasil in the Nordic countries. EUROGIN 2013, Florence, Italy, November 3-6, 2013. abstract (http://www.eurogin.com/2013/images/pdf/EUROGIN-2013-Abstracts-Part-2.pdf).